Equity Overview
Price & Market Data
Price: $4.29
Daily Change: -$0.072 / 1.68%
Daily Range: $4.27 - $4.40
Market Cap: $413,506,976
Daily Volume: 675,419
Performance Metrics
1 Week: -0.92%
1 Month: 22.10%
3 Months: 15.24%
6 Months: -13.63%
1 Year: -37.35%
YTD: 14.02%
Company Details
Employees: 166
Sector: Health technology
Industry: Biotechnology
Country:
Details
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.